-
NK Celltech and RongCan Biotech Partner to Advance mRNA NK Cell Therapy and LNP Delivery System
•
Shanghai-based NK Celltech and RongCan Biotech have entered into a partnership agreement to establish a long-term collaboration in the field of LNP delivery systems, aiming to bolster the clinical application of mRNA on NK cell therapy. The financial details of the agreement have not been disclosed. Complementary Expertise and PlatformsNK…
-
RongCan Biotech Raises Pre-Series A Funding for mRNA Therapeutics Development
•
China-based nucleic acid-based therapeutics developer RongCan (Shanghai) Biotech Co., Ltd has reportedly raised “tens of millions” of renminbi in a Pre-Series A financing round led by a “reputational healthcare fund.” The proceeds will be used to accelerate product research and development (R&D), team building, and clinical studies for leading pipelines.…
